DEA facilitates cannabis research
In the United States, the agency responsible for classifying cannabis as a dangerous drug is the DEA. The Drug Enforcement Administration had announced that it would reclassify cannabis as a dangerous drug sometime this year. That will not happen, but the government drug agency will make it easier for researchers to access cannabis.
For Professor Robert Sievers, this is a major step forward: »If things go as planned, this could mark the dawn of the cannabinoid pharmaceutical industry.» The DEA would grant researchers the right to grow and study cannabinoids completely legally. Basically, there would be no more limits on experimentation for researchers. An optimist, he has been waiting three years for authorization from the DEA to study the plant.
We had our doubts about the intentions of the DEA in April And the prediction was correct. The DEA will not reclassify cannabis as a controlled substance. Marijuana is therefore considered on the same level as heroin.
Access would be easier, but the barriers posed by the federal ban remain in place. In states where cannabis remains illegal, research into new, ultra-potent strains will continue to be complicated. Dr. Jacci Bainbridge, a professor at a pharmacy school, states: »It’s as if they’re showing us the way, but the path is littered with obstacles.».
The National Cannabis Divide
Cannabis is a divisive issue: some people can sell their cannabis freely, while researchers are unable to obtain enough to study those lovely little buds. For now, only the University of Mississippi’s laboratory can legally obtain cannabis.
Furthermore, the DEA still classifies medical cannabis as illegal, which means that thousands of dispensaries in half of all states are distributing treatments that are still illegal.
Researchers hope that with easier access to cannabis, they will be able to prove to the DEA that classifying it as a dangerous drug is inappropriate. By being able to study the plant from seed to flowering, researchers would surely uncover secrets that are still unknown. The public would also have easier access to information. It will still be necessary to convince universities to allocate funds for growing the drug, but its therapeutic potential could very quickly win them over.
Théo Caillart
Via The Cannabist
-
Cannabis in Europe4 weeks ago
Bosnia and Herzegovina Continues to Roll Out Medical Cannabis Following Its Legalization
-
Cannabis in France3 weeks ago
France Submits the Long-Awaited Decree on the Reimbursement of Medical Cannabis to the Council of State
-
Cannabis in the U.S.4 weeks ago
The DEA Begins Hearings on the Federal Rescheduling of Cannabis
-
Business3 weeks ago
China Invests $10 Million in Medical Cannabis in Lebanon
-
Cannabis in Thailand4 weeks ago
Thailand Threatens Cannabis Shops with Severe Penalties
-
Business4 weeks ago
The British medical cannabis market is expected to exceed 140,000 patients by 2026
-
Cannabis in Australia2 weeks ago
South Australia is working to identify more water-efficient hemp varieties
-
Exchange4 weeks ago
Glass House will be the second U.S. cannabis company to list on the New York Stock Exchange


You must be logged in to post a comment Login